NDAORALTABLET
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
JENTADUETO (linagliptin and metformin hydrochloride) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2012.
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JENTADUETO is a fixed-dose combination tablet containing linagliptin (a DPP-4 inhibitor) and metformin hydrochloride for the treatment of type 2 diabetes mellitus. It works by increasing incretin levels to improve glucose control, combining a newer mechanism (DPP-4 inhibition) with the established efficacy of metformin. The oral tablet is designed to simplify regimen adherence in patients requiring dual therapy.
$94MPart D
PeakStable
11.1 years to LOEAt peak lifecycle with $94M in Part D spending, JENTADUETO maintains stable commercial performance but operates in a mature competitive space requiring experienced brand stewardship teams.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.
Started Nov 2013
36 enrolled
Healthy
Career Relevance
JENTADUETO roles are concentrated in commercial and market access functions supporting a stable, mature brand in an increasingly competitive therapeutic area. Career growth on this product involves managing market share defense against newer mechanisms and internal portfolio competition rather than driving expansion or innovation.
Brand Manager
Worked on JENTADUETO at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.